Zobrazeno 1 - 10
of 72
pro vyhledávání: '"Nicolas, Paleiron"'
Autor:
Laurent Guilleminault, Claire Camus, Chantal Raherison-Semjen, Audrey Capdepon, Arnaud Bourdin, Philippe Bonniaud, Stéphanie Fry, Gilles Devouassoux, François-Xavier Blanc, Christophe Pison, Clairelyne Dupin, Naji Khayath, Joelle Courdeau, Judith Valcke-Brossollet, Cécilia Nocent-Ejnaini, Fabien Rolland, Carmen Lamandi, Alain Proust, Anaig Ozier, Laurent Portel, Wanda Gaspard, Pauline Roux-Claude, Antoine Beurnier, Stéphanie Martinez, Jean-Marc Dot, Florence Hennegrave, Guillaume Vignal, Etienne Auvray, Nicolas Paleiron, Nicolas Just, Jean Miltgen, Maud Russier, Cécile Olivier, Camille Taillé, Alain Didier
Publikováno v:
Therapeutic Advances in Respiratory Disease, Vol 17 (2023)
Background: Biological therapies have revolutionized the treatment of severe asthma with type 2 inflammation. Although such treatments are very effective in reducing exacerbation and the dose of oral steroids, little is known about the persistence of
Externí odkaz:
https://doaj.org/article/c75b2e5e63204908b0c7dc6bd3893d10
Autor:
Alain Vergnenegre, Margaux Geier, Florian Guisier, Regine Lamy, Bénédicte Comet, Gwenaelle Le Garff, Pascal Do, Henri Janicot, Hugues Morel, Chantal Decroisette, Michel Andre, Lionel Falchero, Nicolas Paleiron, Isabelle Monnet, the GFPC Team
Publikováno v:
Cancer Medicine, Vol 9, Iss 2, Pp 432-439 (2020)
Abstract Background Immune checkpoint inhibitors (ICIs) have been approved as second‐line therapy for advanced non–small cell lung cancers (NSCLCs) progressing after platinum‐based chemotherapy. However, some patients' disease progressed rapidl
Externí odkaz:
https://doaj.org/article/f888be4cb547443ca22958a679b90330
Autor:
Charlotte Baltazard, Pierre Julien Cunji, Olivier Bylicki, Claudia Natale, Fabien Beranger, Elodie Rive, Nicolas Paleiron, Guillaume Lacroix, Jean-Philippe Avaro, Laurys Boudin, Henri de Lesquen
Objectives To determine if ambulatory videothoracoscopic pleural sampling followed by indwelling pleural catheter (VATS-IPC) is safe and effective comparing with videothoracoscopic talc pleurodesis (VATS-TP) reducing total pleural effusion-relative h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::92d432edf6303a5ce84a9d9b08f31ce0
https://doi.org/10.21203/rs.3.rs-2799992/v1
https://doi.org/10.21203/rs.3.rs-2799992/v1
Autor:
Alexandre Fauché, Emilie Presles, Olivier Sanchez, Xavier Jaïs, Raphael Le Mao, Philippe Robin, Gilles Pernod, Laurent Bertoletti, Patrick Jego, Florence Parent, Catherine A. Lemarié, Florent Leven, Pierre‐Yves Le Roux, Pierre‐Yves Salaun, Michel Nonent, Philippe Girard, Karine Lacut, Laurent Savale, Solen Mélac, Marie Guégan, Patrick Mismetti, Silvy Laporte, Christophe Leroyer, David Montani, Francis Couturaud, Cécile Tromeur, Guy Meyer, Elisabeth Duhamel, Karine Provost, Dominique Mottier, Aurélia Le Hir, Stéphane Lenoir, Christian Lamer, Jean François Bergmann, Denis Wahl, Ludovic Drouet, Patrick Chevarier, Nicolas Monte, Florence Morvan, Véronique Kouassi, Nabahats Ibrir, Gaid El Asri, Pierre Yves Salaun, Pierre Yves Le Roux, Luc Bressollette, Philippe Quéhé, Simon Gestin, Jérôme Bahuon, Lucille Deloire, Benjamin Planquette, Yannick Jobic, Yves Etienne, Romain Didier, Loic Leroux, Hubert Galinat, Cédric Le Maréchal, Lénaïck Gourhant, Fanny Mingant, Emmanuelle Lemoigne, Luc De Saint Martin, Aurélien Delluc, Grégoire Le Gal, Nicolas Paleiron, Raphaël Le Mao, Christophe Pison, Philippe Guéret, Hervé Décousus, Sandrine Accassat
Publikováno v:
Journal of Thrombosis and Haemostasis
Journal of Thrombosis and Haemostasis, 2022, 20 (12), pp.2850-2861. ⟨10.1111/jth.15866⟩
Journal of Thrombosis and Haemostasis, 2022, 20 (12), pp.2850-2861. ⟨10.1111/jth.15866⟩
International audience; Background: Chronic thromboembolic pulmonary hypertension (CTEPH) is a life-threatening pulmonary embolism's (PE) complication whose incidence and predictors are not precisely determined.Objective: To determine the frequency a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a02aa673c913404a0d78cb9a0aded90a
https://hal-univ-rennes1.archives-ouvertes.fr/hal-03800679/document
https://hal-univ-rennes1.archives-ouvertes.fr/hal-03800679/document
Autor:
Jean-Marc VALLIER, Charles SIMON, Antoine BRONSTEIN, Maxence DUMONT, Asmaa JOBIC, Nicolas PALEIRON, Laurent MELY
Publikováno v:
European Journal of Physical and Rehabilitation Medicine. 59
Autor:
Christos Chouaïd, Nicolas Paleiron, Radj Gervais, Gaelle Rousseau-Bussac, LaurenceBigay Game, AnneMarie Chiappa, Regine Lamy, Florian Guisier, Hervé Le Caer, Gilles Robinet, Acya Bizieux, null GFPC
Publikováno v:
Journal of cancer research and therapeutics. 18
Few data have been published on the management of patients with synchronous head-and-neck cancer (HNC) and lung cancer (LC). This observational study was undertaken to describe the management of these patients in multiple centers.All patients consecu
Autor:
Bertrand Elie, Aude Valois, Julien Pontis, Emilie Rivière, Cyprien Chartois, Nicolas Paleiron
Publikováno v:
Military Medicine. 187:e906-e914
Introduction According to the literature, 8% of the population claim to have an allergy to penicillin. Allergy tests show that 90% of these patients tolerate this molecule. Physicians working in the French Navy are faced with situations of real isola
Publikováno v:
OncoTargets and Therapy. 13:5691-5706
The c-MET proto-oncogene (MET) plays an important role in lung oncogenesis, affecting cancer-cell survival, growth and invasiveness. The MET receptor in non-small-cell lung cancer (NSCLC) is a potential therapeutic target. The development of high-out
Autor:
Jacques Le Treut, Catherine Dubos-Arvis, O. Bylicki, Alain Vergnenegre, Jacky Crequit, Marie Marcq, Gwenaelle Le Garff, Nicolas Paleiron, Victor Basse, Isabelle Monnet, Pascal Thomas, Gislaine Fraboulet, Bénédicte Comet, Anne Madroszyk, Jean-Bernard Auliac
Publikováno v:
Cancer Management and Research. 11:10821-10826
Background Antiangiogenic agents have improved the prognosis of non-squamous non-small-cell lung cancers (NSCLCs), even though all the patients are not eligible to receive them because of counterindications linked to the tumor's characteristics or co
Autor:
Hugues Morel, R. Lamy, Alain Vergnenegre, Gfpc Team, H. Janicot, Nicolas Paleiron, Isabelle Monnet, Michel Andre, Florian Guisier, Chantal Decroisette, Pascal Do, Bénédicte Comet, Lionel Falchero, Gwenaelle Le Garff, Margaux Geier
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 9, Iss 2, Pp 432-439 (2020)
Cancer Medicine, Vol 9, Iss 2, Pp 432-439 (2020)
Background Immune checkpoint inhibitors (ICIs) have been approved as second‐line therapy for advanced non–small cell lung cancers (NSCLCs) progressing after platinum‐based chemotherapy. However, some patients' disease progressed rapidly and som